APA (7th ed.) Citation

HL, M., A, T., AP, T., JV, W., JA, B., JA, E., . . . FS, D. (2024). Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. MMWR. Morbidity and mortality weekly report, 73(9), 209. https://doi.org/10.15585/mmwr.mm7309a4

Chicago Style (17th ed.) Citation

HL, Moline, et al. "Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024." MMWR. Morbidity and Mortality Weekly Report 73, no. 9 (2024): 209. https://doi.org/10.15585/mmwr.mm7309a4.

MLA (9th ed.) Citation

HL, Moline, et al. "Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024." MMWR. Morbidity and Mortality Weekly Report, vol. 73, no. 9, 2024, p. 209, https://doi.org/10.15585/mmwr.mm7309a4.